By Nate Wolf

Insulet stock was climbing Friday after the insulin pump maker's results beat earnings expectations and raised its forecast for the rest of 2025.

The company reported first-quarter earnings of $1.02 a share and $569 million in revenue, beating Wall Street's consensus estimates of 79 cents a share and $543 million, respectively.

Insulet was the best performer in the S&P 500 on Friday, with its shares up 17% to $300.01.

In Thursday's earnings release, management boosted guidance for full-year revenue growth to a range of 19% to 22%, up from a previous forecast of 16% to 20%.

"Our first-quarter results showcase the strong execution and dedication of the Insulet team," said CEO Ashley McEvoy. "I see a path to scale the Company from an emerging diabetes leader to a durable growth engine."

Insulet stock has soared 81% over the last 12 months, buoyed by the Food and Drug Administration's approval of the company's Omnipod 5 Insulin System for adults with Type 2 diabetes last August.

Wall Street sees potential for the stock to rise even further.

Analysts at Oppenheimer maintained their Outperform rating and bumped their price target to $324 from $312, citing the launch of Omnipod 5 in international markets this year and the product's continued rollout in the U.S.

Jayson Bedford and Elaine Cui of Raymond James also reiterated their Outperform rating and $328 price target, calling Insulet "worthy of a higher stock price."

Write to Nate Wolf at nate.wolf@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

May 09, 2025 10:11 ET (14:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.